Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 7:35AM CST Zacks Equity Research - ZACKS - Fri Feb 21, 7:35AM CST Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately. Zacks Investment Research Upgrades Aptose Biosciences ... Aptose Biosciences (NASDAQ:APTO) (TSE:APS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Monday, Zacks.com reports. The firm currently has a $6.00 price objective on the biotechnology company’s stock. APTO | Aptose Biosciences Inc. Profile | MarketWatch Nov 01, 2019 · Aptose Biosciences Inc. company facts, information and stock details by MarketWatch. View apto business summary and other industry information.
Jan 01, 2010 · Aptose Biosciences (NASDAQ: APTO) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on
Maxim Group Begins Coverage on Aptose Biosciences (NASDAQ ... Maxim Group began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report report published on Thursday, Benzinga reports. The brokerage issued a buy rating and a $16.00 price objective on the biotechnology company’s stock. Aptose Biosciences Inc. (NASDAQ:APTO) CEO Buys $19,788.00 ... Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) CEO William G. Rice acquired 3,400 shares of the stock in a transaction dated Wednesday, March 25th. The shares were bought at an average cost of $5.82 per share, for a total transaction of $19,788.00. Following the completion of the transaction, the chief executive officer now owns 466,414 shares in […] Aptose Biosciences: 4Q Earnings Snapshot Mar 10, 2020 · TORONTO (AP) _ Aptose Biosciences Inc. (APTO) on Tuesday reported a loss of $7.7 million in its fourth quarter. The Toronto-based company said it had a loss of 13 cents per share. The results exceeded Wall Street expectations. The average estimate of …
APTO Stock Price | Aptose Biosciences Inc. Stock Quote (U ...
Maxim Group Begins Coverage on Aptose Biosciences (NASDAQ ... Maxim Group began coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a research report report published on Thursday, Benzinga reports. The brokerage issued a buy rating and a $16.00 price objective on the biotechnology company’s stock. Aptose Biosciences Inc. (NASDAQ:APTO) CEO Buys $19,788.00 ... Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) CEO William G. Rice acquired 3,400 shares of the stock in a transaction dated Wednesday, March 25th. The shares were bought at an average cost of $5.82 per share, for a total transaction of $19,788.00. Following the completion of the transaction, the chief executive officer now owns 466,414 shares in […] Aptose Biosciences: 4Q Earnings Snapshot Mar 10, 2020 · TORONTO (AP) _ Aptose Biosciences Inc. (APTO) on Tuesday reported a loss of $7.7 million in its fourth quarter. The Toronto-based company said it had a loss of 13 cents per share. The results exceeded Wall Street expectations. The average estimate of … APTO:NASDAQ CM Stock Quote - Aptose Biosciences Inc ...
Aptose Biosciences Inc. (NASDAQ:APTO) Receives $10.25 ...
Aptose Biosciences, Inc. Common Shares (APTO) Earnings ... Aptose Biosciences, Inc. is estimated to report earnings on 03/10/2020. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Aptose Biosciences Inc. (NASDAQ:APTO) Receives $10.25 ...
Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) CEO William G. Rice acquired 3,400 shares of the stock in a transaction dated Wednesday, March 25th. The shares were bought at an average cost of $5.82 per share, for a total transaction of $19,788.00. Following the completion of the transaction, the chief executive officer now owns 466,414 shares in […]
APTO Stock Quote of Aptose Biosciences Inc - InvestorPlace Check out our APTO stock analysis, current APTO quote, charts, and historical prices for Aptose Biosciences Inc stock feedback@investorplace.com. From Zacks Investment Research Mar 6, 2020